NCT06128629: An ongoing trial by Intellia Therapeutics
This trial is ongoing. It must report results 3 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06128629 |
|---|---|
| Title | MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 13, 2023 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 16, 2025 |
| Days late | None |